EUVIMEDEUVIMED entdecken
Crossref

Improved early transplant outcomes with reduced‐dose PTCy and low‐dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia

Nihar Desai iD, Mohammed Althobaiti, Carol Chen, Eshrak Al-Shaibani iD, Tommy Alfaro Moya iD, Igor Novitzky-Basso, Ivan Pasic iD, Fotios V Michelis, Dennis D Kim, Rajat Kumar iD, Jonas Mattsson, Arjun D Law und 1 weitere

British Journal of Haematology · 2026-04 · 208 (4) · 1359-1368

DOI: 10.1111/bjh.70380 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 26.02.2026. Verfasst von Nihar Desai und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toron…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antilymphocyte Serum, Cyclophosphamide, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Post‐transplant cyclophosphamide (PTCy) is associated with infectious and organ toxicities. Dose optimization may reduce these risks while maintaining efficacy. We initiated a prospective pilot study in July 2024 evaluating reduced‐dose PTCy (35 mg/kg on days +3 and +4; PTCy70) with low‐dose anti‐thymocyte globulin (ATG) (2 mg/kg) in adults with acute myeloid leukaemia (AML) undergoing matched unrelated donor (MUD) transplantation. Outcomes were compared with a contemporary cohort receiving PTCy100 with ATG 2 mg/kg. Of 173 patients, 41 received PTCy70. Platelet engraftment was faster with PTCy70, 13 vs. 16 days ( p < 0.001). In multivariable analysis, PTCy70 was associated with lower risk of bloodstream infections (hazard ratio [HR] 0.39, 95% confidence interval [CI], 0.19–0.78, p = 0.007). At day+100, the incidence of grade II–IV (30.4% vs. 20.3%, p = 0.17), grade III–IV acute graft‐versus‐host disease (GVHD) (3% vs. 3%, p = 0.08) and non‐relapse mortality (3.8% vs. 2.8%, p = 0.67) were similar between groups. Cardiac events were less frequent with PTCy70 (5% vs. 17%; p = 0.06). No cases of sinusoidal obstruction syndrome were observed in the PTCy70 group. At 12 months, relapse (11.1% vs. 15.3%, p = 0.88) and overall survival (79.6% vs. 83.2%, p = 0.87) did not differ between groups. PTCy70 was associated with faster platelet engraftment, fewer bloodstream infections and cardiac events without compromising GVHD, relapse or survival, supporting evaluation in randomized trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteAntilymphocyte SerumCyclophosphamideHematopoietic Stem Cell TransplantationHumansFemaleMiddle AgedMaleAdultUnrelated DonorsTransplantation, HomologousAgedGraft vs Host DiseaseProspective StudiesTreatment OutcomePilot ProjectsTransplantation Conditioning

Stichwörter der Autor:innen

AMLGVHDPTCyallogeneic transplantationreduced‐doseunrelated donor

Substanzen

Antilymphocyte SerumCyclophosphamide

Autor:innen und Institutionen

  • Hans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Nihar Desai, Eshrak Al-Shaibani, Tommy Alfaro Moya, Ivan Pasic, Rajat Kumar

Zitieren

APA

Desai, N., Althobaiti, M., Chen, C., Al-Shaibani, E., Moya, T. A., Novitzky-Basso, I., Pasic, I., Michelis, F. V., Kim, D. D., Kumar, R., Mattsson, J., Law, A. D., & Viswabandya, A. (2026). Improved early transplant outcomes with reduced‐dose PTCy and low‐dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia. British Journal of Haematology, 208(4), 1359-1368. https://doi.org/10.1111/bjh.70380

Vancouver

Desai N, Althobaiti M, Chen C, Al-Shaibani E, Moya TA, Novitzky-Basso I, et al. Improved early transplant outcomes with reduced‐dose PTCy and low‐dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia. British Journal of Haematology. 2026;208(4):1359-1368. doi:10.1111/bjh.70380

BibTeX
@article{Desai2026,
  author = {Desai, Nihar and Althobaiti, Mohammed and Chen, Carol and Al-Shaibani, Eshrak and Moya, Tommy Alfaro and Novitzky-Basso, Igor and Pasic, Ivan and Michelis, Fotios V and Kim, Dennis D and Kumar, Rajat and Mattsson, Jonas and Law, Arjun D and Viswabandya, Auro},
  title = {Improved early transplant outcomes with reduced‐dose PTCy and low‐dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {208},
  number = {4},
  pages = {1359--1368},
  doi = {10.1111/bjh.70380}
}
Kostenlos starten →